The global COVID-19 pandemic has had a major impact on our healthcare system and economic activity. The major challenge is to better understand the pathology to better diagnose, treat and prevent it. Any significant progress in these different areas of COVID-19 will have a direct economic impact in the short term (maintenance of activity and creation of jobs and businesses) and in the long term by ensuring the return to employment of patients. The SARS-CoV2 infection responsible for COVID-19 is characterised initially by an important viral replication phase and then an inflammatory phase characterised by major alterations of the innate and adaptive immune system that can be accompanied by a cytokinic storm participating in respiratory and visceral failure. COVID-19 is therefore the paradigm of infectious disease responsible for an unsuitable and deleterious immmunoinflammatory reaction that is responsible for most deaths in this pathology. Its management is therefore based on antiviral strategies but also on immunomodulatory treatments and prevention through a vaccine strategy. To describe and understand these immuno-inflammatory alterations, their relationship with the severity of the disease, particularly the lung disease, and to analyse the mechanisms of this severity as well as the immunological response, are fundamental for short-term treatment and vaccine strategy. These are the objectives of the COVID-2 project